HA12630 10-Deacetylbaccatin III 10-DAB Powder (CAS No.: 32981-86-5)

10-Deacetylbaccatin III 10-DAB Powder (CAS No.: 32981-86-5) Description

The compound is a deacetylated derivative of baccatin III employed as a precursor in chemical synthesis. It is processed to exhibit a reproducible particle size distribution and controlled impurity profile. The defined reactivity facilitates its use in constructing semisynthetic taxane derivatives, while stringent chromatographic quality checks ensure its suitability for laboratory-scale applications.

10-Deacetylbaccatin III 10-DAB Powder (CAS No.: 32981-86-5) Applications

1.       Pharmaceutical Synthesis
   - Used as an intermediate in the production of semisynthetic taxane derivatives to achieve controlled molecular modifications by leveraging its defined reactivity profile.
   - Employed as a reactive agent in precursor conversion for anticancer drug formulations by utilising its verified purity.

2.       Academic and Industrial Research
   - Applied as a model compound in mechanistic studies of deacetylation reactions to elucidate reaction pathways by capitalising on its reproducible chemical structure.
   - Often used as a benchmark material in analytical method development to ensure consistency in experimental results.

10-Deacetylbaccatin III 10-DAB Powder (CAS No.: 32981-86-5) Packing

The powder is packaged in high-density polyethylene (HDPE) containers equipped with airtight seals to prevent moisture ingress. An inner anti-static lining and protective foam ensure minimal mechanical stress and contamination during handling and transport. The packaging supports controlled storage conditions with options for customised labelling and tamper evidence. Recommended storage conditions include a cool, dry environment to preserve chemical integrity.

Additional Information

10-Deacetylbaccatin III 10-DAB Powder plays a significant role as a chemical intermediate in the synthesis of complex organic molecules. Understanding its reactivity, structure, and thermal behaviour is essential for optimising chemical transformations in pharmaceutical research. Detailed analytical characterisation, including chromatographic separation and spectroscopic validation, enables scientists to predict and replicate reaction outcomes reliably.

Advances in materials science and chemical processing have improved the methods available for verifying compound purity and consistency. The integration of calibrated instrumentation within quality control protocols minimises batch-to-batch variability, thereby supporting reproducible research outcomes and facilitating the development of effective synthesis strategies.